Clinical trial Recruiting at 4 sites Interventional Ages 18 to 65

Dynavisc to reduce pain after revision carpal tunnel surgery

Official title: A Multicenter, Evaluator-Blinded, Randomized Evaluation of DYNAVISC in Pain Reduction Following Revision Surgery for Persistent or Recurrent Carpal Tunnel Syndrome

Run by FzioMed · NCT06593977 · Data updated 2026-11-12

This study will test whether applying Dynavisc around the median nerve reduces pain in adults who have persistent or recurrent carpal tunnel symptoms after prior surgery.

More Carpal Tunnel Syndrome (CTS) trials

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment50 (estimated)
SponsorFzioMed
Industry-sponsored
Locations4 sites (Leuven, Belgium and 3 other locations)
StatusRecruiting
StartedMarch 26, 2026
Main results expectedAugust 2029
Study endsOctober 2029
Registry record updatedSeptember 2, 2026
Trial IDNCT06593977 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18–65 in generally good health who have recurrent or persistent symptoms in the same hand after prior carpal tunnel release, with at least one positive clinical test (Phalen, Tinel, or monofilament) and ENMG findings consistent with CTS are ideal candidates.

Probably not a fit

Patients outside the 18–65 age range, those with other causes of hand pain or severe systemic disease, or those unable to attend follow-up visits are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter, randomized, evaluator-blinded trial enrolling adults with recurrent or persistent carpal tunnel syndrome after prior release. Participants undergo standard-of-care revision surgery and are randomized to have the median nerve covered with Dynavisc or with a hypothenar fat pad flap, with 25 participants planned per group. Outcomes include patient-reported pain (VAS), hand function (QuickDASH), neuropathic pain (DN4), nerve conduction studies, and grip strength measured at baseline and at 1, 4, and 12 weeks postoperatively. Patients will begin gentle finger and wrist mobilization immediately and resume strenuous activity at six weeks, and assessments are performed by personnel blinded to treatment assignment.

Why it matters

Potential benefit: If successful, Dynavisc could lower postoperative pain and improve nerve recovery and hand function after revision carpal tunnel surgery.

How similar studies have gone: Anti-adhesion and nerve coverage approaches have shown promise in smaller series, but randomized evidence specifically supporting Dynavisc for revision carpal tunnel is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion criteria

* Signed and dated informed consent form;
* Stated willingness to comply with all study procedures and availability for the duration of the study;
* Aged 18-65 years of age;
* In good general health;
* Patients experiencing recurrence or persistence of pain in the ipsilateral hand after previous carpal tunnel release for surgical treatment of primary carpal tunnel syndrome;
* All of the following physical examination tests must be performed; at least one must be positive:

  1. Physical examination demonstrates positive Phalen test;
  2. Physical examination demonstrates positive Tinel's test;
  3. Physical examination demonstrates positive monofilament test;
* ENMG demonstrates median nerve velocity and deviation consistent with the diagnosis of carpal tunnel syndrome.

Exclusion criteria

* Inability to understand the clinical trial and/or sign the Informed Consent;
* Unable or unwilling to attend all of the study prescribed visits and data collection forms;
* Active infection requiring medication;
* Drug requiring diabetes mellitus;
* Collagenopathies;
* Hypothyroidism requiring medication;
* Rheumatoid arthritis requiring medication;
* Autoimmune disease requiring medication;
* Cervical nerve compression;
* Hematopoietic disorders;
* Lacertus fibrosis;
* Psychiatric disorder requiring medical treatment;
* Subject of workers compensation claim;
* History of cancer, except for basal or squamous cell skin cancer;
* Known allergic reactions to components of DYNAVISC;
* Actively participating in another clinical trial.

Where it's running

  • UZ Leuven
    Leuven, Belgium, Belgium
    Recruiting
  • AZ Delta
    Roeselare, Belgium, Belgium
    Recruiting
  • Hospital Angelina Caron
    Araçatuba, Brazil, Brazil
    Recruiting
  • Azienda Ospedale Universita Padova
    Padova, Italy, Italy
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.